Results 161 to 170 of about 331,825 (303)

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Efficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies

open access: yes, 2016
Xun Jin,1 Peilan Zhang,1 Li Luo,1 Hao Cheng,1 Yunzu Li,1 Ting Du,1 Bingwen Zou,2 Maling Gou1 1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu ...
Li Y   +7 more
core  

Digital diagnostics, biomarkers and therapeutics in an evolving healthcare system: From promise to practice

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop   +3 more
wiley   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong   +6 more
wiley   +1 more source

Urinary Extracellular Vesicles for High-Precision Bladder Cancer Subtyping and Prognosis. [PDF]

open access: yesJ Extracell Biol
Greenberg ZF   +5 more
europepmc   +1 more source

Fever and leukemoid reaction in bladder cancer: A case report. [PDF]

open access: yesOncol Lett
Huang T   +8 more
europepmc   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

open access: yesBMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan   +8 more
wiley   +1 more source

Enhanced Imaging in Bladder Cancer: Fluorescence Cystoscopy and Molecular Diagnostics. [PDF]

open access: yesLife (Basel)
Godlewski D   +6 more
europepmc   +1 more source

Marine silicon for biomedical sustainability

open access: yesBMEMat, EarlyView.
Schematic illustrating marine silicon for biomedical engineering. Abstract Despite momentous divergence from oceanic origin, human beings and marine organisms exhibit elemental homology through silicon utilization. Notably, silicon serves as a critical constituent in multiple biomedical processes.
Yahui Han   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy